• Enkam presents new results at the Society for Neur
• Commercial Partnership with STEMCELL Technologies
• ENKAM Pharmaceuticals Engages The Sage Group as Ad
• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

Enkam presents new results at the Society for Neuroscience, demonstrating advantages of its stem cell programs with relevance for treating CNS disorders and cancer ____________________________________________________

ENKAM Pharmaceuticals A/S, the Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, announces today that it will present new exciting stem cell data at the Society for Neuroscience to be held 17-21 October 2009 in Chicago.

At the conference ENKAM will present posters on two novel classes of drug-candidates with a great potential as pharmacological modulators of human cord blood derived stem cell - Inherbin3 relevant for treatment of cancer and Artefin1 relevant for treatment of neurodegenerative disorders.

The work has been done in collaboration with Professor Colin McGUCKIN and his team at CTI-Lyon, Cell Therapy Research Institute of Lyon France.

Several of the synthetic NCAM and growth factor derived peptides which were tested in the study promoted the survival and neuronal differentiation of human cord blood-derived stem cells, indicating their potential as pharmacological modulators.

In particular human cord blood stem cell cultures treated with the peptides Artefin1 and Inherbin3 gave rise to a heterogeneous cellular composition of neural stem cells in brain which is promising for transplantation and tissue engineering.

Inherbin3 is in development for treatment of cancer and is a partial agonist to the ERB1-4 receptors. It has recently demonstrated in vivo effects similar to Taxol in a xenograft model using the lung cancer cell line (A549), possibly mediated through an effect on cancerous stem cells.

Artefin1 is derived from artemin, a member of the GDNF family of growth factors. NCAM (the Neural Cell Adhesion Molecule) is likely to play a significant role in the effect of the GDNF growth factor family. This finding has just been published in The Journal of Neuroscience by the scientific founders of Enkam. NCAM also has a regulatory role as seen with other growth factor receptors (e.g. FGF), but in this case by a direct binding of GDNF to NCAM.

Commenting on this announcement, Morten Albrechtsen MD, Chief Executive and a founder of ENKAM Pharmaceuticals, said: "We are pleased to see a growing picture of the effects of the NCAM mediated peptides which work by modulating the growth factors and associated receptors with significant effects on stem cells; this is likely to have relevance within both cancer and CNS therapeutic applications."

Commenting on this announcement, Professor Colin McGUCKIN from CTI-Lyon, cell therapy research institute of Lyon France, said:

"Stem cell differentiation to advance biomedical research requires translational collaborations between scientists and biotechnology companies. Enkam's peptide technology provided optimal conditions for human umbilical cord blood stem cell-based tissue engineering into neural tissues."

In 2009, ENKAM successfully completed the formulation, clinical manufacture and preliminary toxicology testing of a novel single-stranded peptide, FGLs, allowing both subcutaneous and intranasal administration of this potentially important neuroactive peptide. The FGLs clinical development plan will continue now beyond Phase 1 via strategic corporate partnering. Advanced partnering discussions are ongoing and are being managed by The Sage Group.

FGLs is a peptide which mimics the neural cell adhesion molecule (NCAM), which is known to work by protecting neuronal cells. Its activity re-establishes cognitive function by promoting the connectivity between cells resulting in the formation of new neurons from neural stem cells or neural progenitors. FGLs has been developed for the treatment of Alzheimer's disease, the most common form of dementia, estimated to affect approximately 15 million patients worldwide, including four million in the USA. The number of Alzheimer patients is expected to grow exponentially in the future, and ENKAM believes its therapeutic approaches are well placed to make a significant impact in this sector.

For enquiries please contact:

Notes for Editors

About ENKAM

ENKAM Pharmaceuticals A/S is a biopharmaceutical development company focused on cancer and CNS disorders. ENKAM's Protein Mimetic Technology Platform (PMTP^TM) allows the creation of active peptides which mimic specific functions of larger proteins. The Company has several compounds in pre-clinical and clinical development for Alzheimer's disease and Huntington's disease as well as for breast and prostate cancer. The Company has a rich inventory of active peptides and the ability to quickly create new peptides which segregate specific activities of multifunctional proteins. The current pipeline of peptide drugs are derived from multifunctional proteins, such as the Neural Cell Adhesion Molecule (NCAM) and the Fibroblast Growth Factors (FGFs).

About CTI-Lyon

CTI-LYON, Cell Therapy research Institute is a non-for-profit organization focused on biomedical research and development from adult and umbilical cord stem cells for cell therapy, regenerative medicine, tissue engineering and biotechnology. CTI-LYON hosts an international team of researchers and state-of-the art facilities dedicated to stem cell expansion and differentiation into various tissues including neural, hepatic and pancreatic tissues. CTI-LYON collaborates internationally with academic and clinical research groups as well as industry.